Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine in Thai Children Aged 5-11 Years
TCTR20220125002Phase 2Completed
- Sponsor
- National Vaccine Institute
- Start
- Feb 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of LVRNA021 in coronavirus disease 2019 (COVID-19), sponsored by National Vaccine Institute. Started Feb 2022; status: completed.
02
Drugs
LVRNA021
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20220125002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220125002.